4 results match your criteria: "the Second Hospital of Anhui Medical University (SHAMU)[Affiliation]"
Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Front Immunol
May 2022
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China (USCT) (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Background: While chimeric antigen receptor (CAR)-T cell therapy is becoming widely used in hematological malignancies with remarkable remission rate, their high recurrence remains an obstacle to overcome. The role of consolidative transplantation following CAR-T cell-mediated remission remains controversial. We conducted a retrospective study to explore whether bridging to unrelated cord blood transplantation (UCBT) could improve the prognosis of patients entering remission after CAR-T therapy with different characteristics through subgroup analyses.
View Article and Find Full Text PDFCorrigendum to "CD4CD25CD127 regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia" [Int. Immunopharmacol. 96 (2021) 107742].
Int Immunopharmacol
January 2022
Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China. Electronic address:
CD4CD25CD127 regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.
Int Immunopharmacol
July 2021
Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China. Electronic address:
Article Synopsis
- CD19-specific CAR-T therapy has shown effectiveness in treating relapsed/refractory B-ALL, but some patients experience therapy resistance or relapse.
- Higher levels of regulatory T cells (Tregs) in patients before treatment are linked to poorer survival outcomes, indicating Tregs may play a role in treatment efficacy.
- A study analyzing Treg levels in 46 patients during different stages of CAR-T therapy found that Treg frequencies were notably higher in patients not in remission compared to those who achieved remission.
Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.
Nat Commun
November 2020
Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.
CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy has shown high remission rates in patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL). However, the long-term outcome and the factors that influence the efficacy need further exploration. Here we report the outcome of 51 r/r B-ALL patients from a non-randomized, Phase II clinical trial (ClinicalTrials.
View Article and Find Full Text PDF